Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

86 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.
Dimopoulos MA, Terpos E, Boccadoro M, Delimpasi S, Beksac M, Katodritou E, Moreau P, Baldini L, Symeonidis A, Bila J, Oriol A, Mateos MV, Einsele H, Orfanidis I, Ahmadi T, Ukropec J, Kampfenkel T, Schecter JM, Qiu Y, Amin H, Vermeulen J, Carson R, Sonneveld P; APOLLO Trial Investigators. Dimopoulos MA, et al. Among authors: bila j. Lancet Oncol. 2021 Jun;22(6):801-812. doi: 10.1016/S1470-2045(21)00128-5. Lancet Oncol. 2021. PMID: 34087126 Clinical Trial.
Single-center experience in the treatment of primary testicular lymphoma.
Mihaljevic B, Vukovic V, Smiljanic M, Milic N, Todorovic M, Bila J, Andjelic B, Djurasinovic V, Jelicic J, Antic D. Mihaljevic B, et al. Among authors: bila j. Oncol Res Treat. 2014;37(5):239-42. doi: 10.1159/000362399. Epub 2014 Apr 14. Oncol Res Treat. 2014. PMID: 24853782
Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trial.
Terpos E, Dimopoulos MA, Boccadoro M, Delimpasi S, Beksac M, Katodritou E, Moreau P, Pompa A, Symeonidis A, Bila J, Oriol A, Mateos MV, Einsele H, Orfanidis I, Gries KS, Fastenau J, Liu K, He J, Kampfenkel T, Qiu Y, Amin H, Carson R, Sonneveld P. Terpos E, et al. Among authors: bila j. Am J Hematol. 2022 Apr;97(4):481-490. doi: 10.1002/ajh.26480. Epub 2022 Feb 6. Am J Hematol. 2022. PMID: 35089607 Free article.
Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability.
Bochtler T, Hegenbart U, Cremer FW, Heiss C, Benner A, Hose D, Moos M, Bila J, Bartram CR, Ho AD, Goldschmidt H, Jauch A, Schonland SO. Bochtler T, et al. Among authors: bila j. Blood. 2008 May 1;111(9):4700-5. doi: 10.1182/blood-2007-11-122101. Epub 2008 Feb 27. Blood. 2008. PMID: 18305218 Free article.
Osteolytic lesions marker in multiple myeloma.
Djunic I, Elezovic I, Marinkovic M, Suvajdzic-Vukovic N, Tomin D, Jankovic G, Bila J, Antic D, Vidovic A, Neskovic B, Nikolic-Vukosavljevic D. Djunic I, et al. Among authors: bila j. Med Oncol. 2011 Mar;28(1):237-40. doi: 10.1007/s12032-010-9432-4. Epub 2010 Feb 2. Med Oncol. 2011. PMID: 20127208
86 results